Patents by Inventor Nigel Ten Fleming

Nigel Ten Fleming has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Intranasal Formulation of Epinephrine for the Treatment of Anaphylaxis
    Publication number: 20210069126
    Abstract: This invention relates to pharmaceutical compositions of epinephrine for delivery to the nasal mucosa and methods of treating a subject in acute severe anaphylaxis, bronchospasm or during cardiopulmonary resuscitation (CPR). The composition further comprising agents, that either prevent localized degradation of epinephrine or enhance its absorption in the nasal mucosa to counter anaphylactic effects, symptoms or complications in a subject.
    Type: Application
    Filed: September 18, 2020
    Publication date: March 11, 2021
    Applicant: G2B Pharma, Inc.
    Inventor: Nigel Ten Fleming
  • Intranasal formulation of epinephrine for the treatment of anaphylaxis
    Patent number: 10806709
    Abstract: This invention relates to pharmaceutical compositions of epinephrine for delivery to the nasal mucosa and methods of treating a subject in acute severe anaphylaxis, bronchospasm or during cardiopulmonary resuscitation (CPR). The composition further comprising agents, that either prevent localized degradation of epinephrine or enhance its absorption in the nasal mucosa to counter anaphylactic effects, symptoms or complications in a subject.
    Type: Grant
    Filed: September 7, 2017
    Date of Patent: October 20, 2020
    Assignee: G2B Pharma, Inc.
    Inventor: Nigel Ten Fleming
  • Intranasal Formulation of Epinephrine for the Treatment of Anaphylaxis
    Publication number: 20170368000
    Abstract: This invention relates to pharmaceutical compositions of epinephrine for delivery to the nasal mucosa and methods of treating a subject in acute severe anaphylaxis, bronchospasm or during cardiopulmonary resuscitation (CPR). The composition further comprising agents, that either prevent localized degradation of epinephrine or enhance its absorption in the nasal mucosa to counter anaphylactic effects, symptoms or complications in a subject.
    Type: Application
    Filed: September 7, 2017
    Publication date: December 28, 2017
    Applicant: G2B Pharma Inc.
    Inventor: Nigel Ten Fleming
  • Intranasal formulation of epinephrine for the treatment of anaphylaxis
    Patent number: 9789071
    Abstract: This invention relates to pharmaceutical compositions of epinephrine for delivery to the nasal mucosa and methods of treating a subject in acute severe anaphylaxis, bronchospasm or during cardiopulmonary resuscitation (CPR). The composition further comprising agents, that either prevent localized degradation of epinephrine or enhance its absorption in the nasal mucosa to counter anaphylactic effects, symptoms or complications in a subject.
    Type: Grant
    Filed: June 27, 2013
    Date of Patent: October 17, 2017
    Assignee: G2B Pharma, Inc.
    Inventor: Nigel Ten Fleming
  • Intranasal Formulation of Epinephrine for the Treatment of Anaphylaxis
    Publication number: 20150005356
    Abstract: This invention relates to pharmaceutical compositions of epinephrine for delivery to the nasal mucosa and methods of treating a subject in acute severe anaphylaxis, bronchospasm or during cardiopulmonary resuscitation (CPR). The composition further comprising agents, that either prevent localized degradation of epinephrine or enhance its absorption in the nasal mucosa to counter anaphylactic effects, symptoms or complications in a subject.
    Type: Application
    Filed: June 27, 2013
    Publication date: January 1, 2015
    Applicant: G2B PHARMA INC.
    Inventor: Nigel Ten Fleming